Skip to main content

Table 4 Clinical Events after Treatment for In-stent Restenosis at 5 years

From: Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions

Variables Overall population Matched population
PCB (n = 32) Non-PCB (n = 74) p PCB (n = 25) Non-PCB (n = 25) p
Recurrent ISR at 5 years 8 (25.0) 53 (71.6) < 0.001 6 (24.0) 20 (80.0) < 0.001
All-cause death at 5 years 4 (12.5) 9 (12.2) 0.963 4 (16.0) 3 (12.0) 0.699
Target lesion revascularization at 5 years 5 (15.6) 30 (40.5) 0.006 4 (16.0) 11 (44.0) 0.020
Unplanned major amputation at 5 years 0 (0.0) 1 (1.4) 0.491 0 (0.0) 0 (0.0) 1.000
  1. Categorical variables are expressed as number and percentage, and are calculated based on Kaplan-Meier estimate
  2. ISR indicates in-stent restenosis, PCB paclitaxel-coated balloon